Several early-phase clinical studies have demonstrated that the combination of EGFR and MET inhibitors is effective for NSCLC patients with EGFR mutations and MET amplification after EGFR-TKI treatment failure.27–30 These findings offer valuable insights to guide the selection of subsequent treatment strategies to improve patient outcomes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.